Pentanucleotide Repeat Familial Adult Myoclonus Epilepsy

Executive Summary

Familial Adult Myoclonus Epilepsy (FAME) is an autosomal dominant neurological disorder caused by intronic pentanucleotide repeat expansions of TTTCA inserted within polymorphic TTTTA repeats. The identical repeat motif has been identified in seven functionally unrelated genes (SAMD12, STARD7, MARCHF6, YEATS2, TNRC6A, RAPGEF2, and RAI1), establishing FAME as a unique "repeat motif disease" in which the pathogenic mechanism is entirely independent of the host gene's function. The disease is characterized by cortical tremor beginning in the second decade of life, followed by infrequent generalized tonic-clonic seizures by the third to fourth decade. Recent mechanistic studies have identified RNA toxicity — specifically, sequestration of the neuron-specific splicing regulator NOVA2 by UUUCA RNA foci — as the primary pathomechanism, linking FAME to aberrant alternative splicing of critical ion channels and synaptic genes. Despite growing molecular understanding, FAME remains significantly underdiagnosed due to phenotypic overlap with common conditions and the requirement for specialized long-read sequencing for genetic confirmation.

1. Disease Identity and Classification

1.1 Nomenclature

FAME has been described under multiple names in the literature, reflecting its independent discovery by different research groups:

1.2 Disease Identifiers

• MONDO ID: MONDO:0000160 (epilepsy, familial adult myoclonic)
• Orphanet: ORPHA:86814 (Familial adult myoclonic epilepsy)
• OMIM: Multiple entries by subtype (see Section 3)
• Category: Mendelian, autosomal dominant
• ILAE Classification: Not yet recognized as a distinct epilepsy syndrome

1.3 Inheritance

• Pattern: Autosomal dominant with high penetrance
• Genetic anticipation: Present — earlier onset and increased severity in successive generations, particularly with maternal transmission
• De novo mutations: Not commonly reported; most cases arise within families

2. Clinical Features

2.1 Core Phenotype

FAME presents with a distinctive two-phase clinical course:

Phase 1 — Cortical Tremor (onset: ~2nd decade) - Tremulous, involuntary finger movements — the earliest and most consistent symptom - Fine, irregular, action-induced tremor affecting the distal upper extremities - Cortical origin confirmed by neurophysiological studies (see Section 5) - Often initially misdiagnosed as essential tremor

Phase 2 — Epileptic Seizures (onset: ~3rd–4th decade) - Mean seizure onset age: 36.5 ± 9.0 years (approximately 6.9 years after tremor onset) - Predominant seizure type: generalized tonic-clonic seizures (GTCS) - Seizure frequency: rare (<1/year in 58.8%) or occasional (1–6/year in 37.1%) - Prolonged prodromes reported in 57.7% of patients - Myoclonic seizures also occur

2.2 Additional Clinical Features

2.3 Disease Course

• Generally benign and non-progressive — this distinguishes FAME from progressive myoclonus epilepsies (PMEs)
• Cortical tremor may slowly worsen over decades
• Seizures are typically well-controlled with antiseizure medications
• Quality of life can be significantly affected by persistent myoclonus/tremor
• Some families report mild cognitive decline in later life

2.4 Phenotypic Variability

• Significant intra-familial and inter-familial clinical heterogeneity
• Age of onset, seizure severity, and additional symptoms vary
• Variability may be driven by: TTTCA repeat count, repeat configuration, somatic mosaicism, and modifying genetic factors

3. Genetics

3.1 The FAME Repeat Expansion

All FAME subtypes share the same fundamental mutation: insertion of pathogenic (TTTCA) repeats within an expanded (TTTTA) repeat tract in an intron of the affected gene. The general structure is:

Normal allele:    ...(TTTTA)₅₋₃₀...        (polymorphic, benign)
FAME allele:      ...(TTTTA)exp(TTTCA)exp... (pathogenic)

• TTTTA expansion alone is polymorphic and non-pathogenic
• TTTCA insertion is the pathogenic event
• Total repeat counts average ~848 ± 152 units (TTTTA: ~498 ± 196; TTTCA: ~356 ± 110)
• TTTGA interruptions are sometimes observed

3.2 FAME Subtypes

3.3 Gene Functions (Not Relevant to FAME Pathogenesis)

The seven FAME genes encode proteins with entirely different functions, underscoring the gene-independent nature of the disease:

Critical insight: FAME expansions do NOT alter the expression of their host genes. The pathomechanism is entirely repeat-dependent, not gene-dependent.

3.4 Genotype-Phenotype Correlations

The TTTCA repeat count is the primary driver of phenotypic severity:

• TTTCA count inversely correlates with age at onset for cortical tremor (Spearman's ρ = −0.348, P = 0.005)
• TTTCA count inversely correlates with age at onset for epilepsy (Spearman's ρ = −0.424, P = 0.003)
• Higher TTTCA counts are associated with more severe seizure patterns (OR = 0.988, 95% CI: 0.980–0.995, P = 0.002)
• TTTCA counts increase significantly during parental transmission (P = 0.007), with maternal transmission showing larger increases

3.5 Repeat Instability and Anticipation

• Somatic instability: Extreme — TTTCA repeat sizes ranging from 10 to 647 within affected members of a single family
• Intergenerational instability: Repeat counts tend to increase across generations (especially maternal transmission)
• Genetic anticipation: Successive generations show earlier onset and potentially more severe disease
• Evolutionary origin: Pathogenic (TTTTA)exp(TTTCA)exp alleles arise from non-pathogenic (TTTTA)exp alleles through rare TTTCA insertion events, likely via DNA replication slippage

3.6 Geographic Distribution

FAME subtypes show regional geographic clustering reflecting founder effects: - East Asia (Japan, China): FAME1 (SAMD12) predominates, along with FAME4, FAME6, FAME7 - Europe (Italy, France, Germany): FAME2 (STARD7) and FAME3 (MARCHF6) predominate - Africa (Mali): FAME8 (RAI1) — first FAME type identified on the African continent - FAME almost certainly exists globally but is vastly underdiagnosed outside specialized centers

4. Pathophysiology

4.1 RNA Toxicity: The Primary Mechanism

The most compelling evidence supports an RNA gain-of-function toxicity model:

1. Transcription of expanded TTTCA repeats produces UUUCA-containing RNA
2. RNA foci formation: UUUCA RNA aggregates into nuclear foci in neurons
3. NOVA2 sequestration: The neuron-specific splicing regulator NOVA2 is identified as the key RNA-binding protein that interacts with UUUCA RNA foci
4. NOVA2 redistribution: UUUCA RNA disrupts the normal nuclear distribution of NOVA2
5. Bidirectional relationship: NOVA2 knockdown promotes RNA foci formation, creating a toxic feedback loop
6. Alternative splicing disruption: Shared synaptic-related splicing events are altered in both FAME patient iPSC-neurons and NOVA2 target genes

4.2 What Has Been Ruled Out

• Gene loss-of-function: FAME expansions do NOT alter host gene expression
• RAN translation: No repeat-associated non-AUG translation peptides detected in FAME
• Haploinsufficiency: RAI1 expression levels unchanged in FAME8 patients (despite RAI1 haploinsufficiency causing Smith-Magenis syndrome)

4.3 NOVA2 and the Epilepsy Connection

NOVA2 is a master regulator of neuronal alternative splicing. Protein interaction network analysis (STRING database) reveals high-confidence connections between NOVA2 and critical epilepsy-related genes:

Mechanistic model: NOVA2 sequestration by UUUCA RNA foci → aberrant splicing of ion channels (SCN1A, KCNF1) and neurotransmitter receptors (GABRG2, GLRA2) → disrupted excitation/inhibition balance → cortical hyperexcitability → tremor and seizures.

NOVA2 expression is highest in the cortex (NOVA1 predominates in cerebellum), explaining the preferential cortical involvement in FAME.

4.4 Circuit-Level Pathophysiology

FAME involves dysfunction of the cerebellar-thalamic-cortical loop:

• Cortical hyperexcitability: Confirmed by giant SEPs, enhanced C-reflex, jerk-locked back averaging
• Cerebellar involvement: Neuroimaging and postmortem studies show cerebellar alterations
• Abnormal connectivity: Disrupted functional connectivity between cerebellum and cerebral cortex
• Network disorder: TMS studies reveal altered inhibitory circuits in primary somatosensory cortex and subcortical networks
• Occipital predominance: Interictal epileptiform discharges are occipitally dominant in 72.7% of generalized IEDs
• Sleep-wake paradox: Higher IED index during wakefulness (0.82 ± 0.88/min) vs. NREM sleep (0.04 ± 0.06/min)

4.5 Comparison with SCA37: Same Repeat, Different Mechanism

Spinocerebellar ataxia type 37 (SCA37) is caused by an ATTTC repeat insertion in an Alu element within DAB1 — a nearly identical repeat motif to FAME's TTTCA. However, SCA37 uses a gene-dependent mechanism: the repeat insertion hyperactivates a neurodevelopmental DAB1 enhancer, leading to DAB1 overexpression and abnormal axonal pathfinding. This contrast demonstrates that genomic context determines pathomechanism: the same repeat motif can cause disease via RNA toxicity (FAME) or gene dysregulation (SCA37) depending on its location relative to regulatory elements.

5. Diagnosis

5.1 Clinical Diagnosis

Diagnostic clues: - Adult-onset tremulous finger movements with cortical electrophysiological signature - Family history consistent with autosomal dominant inheritance - Late-onset, infrequent GTCS - Photosensitivity - Benign, non-progressive course (distinguishes from PMEs)

Neurophysiological workup: - EEG: Generalized and/or focal interictal epileptiform discharges; occipitally dominant - Somatosensory evoked potentials (SEPs): Giant cortical potentials (enlarged N20-P25) - Long-latency reflex (C-reflex): Enhanced/present at rest - Jerk-locked back averaging (JLBA): Cortical correlate preceding myoclonus - Corticomuscular coherence analysis: Confirms cortical origin

5.2 Molecular Diagnosis

Critical limitation: Standard genetic testing (Sanger sequencing, short-read NGS, exome sequencing, gene panels) CANNOT detect FAME repeat expansions.

Screening: - Repeat-primed PCR (RP-PCR) targeting known FAME loci - Limitation: may miss atypical configurations or very short expansions

Confirmatory: - Long-read sequencing is the gold standard: - Oxford Nanopore Technology (ONT) with CRISPR-Cas9 enrichment - PacBio HiFi targeted sequencing - Resolves repeat length, motif composition, interruptions, and somatic mosaicism - First targeted clinical diagnostic panel covering all 7 FAME loci developed in 2025 - First commercial clinical long-read diagnosis of FAME3 achieved in 2025

5.3 Differential Diagnosis

5.4 Underdiagnosis

FAME is significantly underdiagnosed due to: 1. Phenotypic overlap with common conditions (essential tremor, JME) 2. Lack of ILAE classification as a distinct syndrome 3. Requirement for specialized long-read sequencing not available in most clinical labs 4. Low awareness among general neurologists and epileptologists 5. Geographic concentration of expertise in Japan and Europe

6. Treatment and Management

6.1 Current Symptomatic Treatment

No disease-modifying therapy exists. Current management is symptomatic:

Perampanel is the most evidence-based treatment, with demonstrated reduction in both clinical symptoms and neurophysiological markers of cortical hyperexcitability (decreased N33 amplitudes, attenuated glutamatergic facilitation, enhanced GABAergic inhibition).

6.2 Emerging Approaches

• Thalamic VIM-DBS (Deep Brain Stimulation): First registered interventional clinical trial for FAME (NCT06593444, not yet recruiting). Targets the ventral intermediate nucleus of the thalamus in refractory cases.
• Repetitive TMS / tDCS: Proposed as potential therapeutic tools targeting cerebellar-cortical circuits, though no formal trials yet.

6.3 Future Disease-Modifying Targets

Based on the RNA toxicity mechanism, several rational therapeutic strategies emerge:

1. Antisense oligonucleotides (ASOs) targeting UUUCA repeat RNA for degradation — analogous to strategies in myotonic dystrophy type 1 and C9orf72-ALS/FTD
2. Small molecules disrupting RNA foci formation or preventing NOVA2-RNA interaction
3. NOVA2 pathway restoration — modulating downstream splicing targets
4. CRISPR-based approaches — direct deletion or contraction of repeat expansions
5. iPSC-neuron drug screening platforms — leveraging patient-derived cellular models for compound identification

6.4 Key Unmet Needs

• No disease-modifying therapy
• No validated biomarkers for disease progression or treatment response
• Very limited clinical trial activity
• Diagnosis requires specialized genetic testing not available in most clinical labs
• No formal natural history study or patient registry

7. Key Mechanistic Insights

7.1 Supported Hypotheses

1. FAME is a repeat motif-dependent disease — the identical TTTCA expansion in seven unrelated genes causes the same phenotype, proving the pathomechanism is repeat-driven, not gene-driven
2. RNA toxicity via NOVA2 sequestration is the primary mechanism — UUUCA RNA foci trap NOVA2, disrupting splicing of synaptic genes
3. TTTCA repeat count drives severity — inverse correlation with onset age, dose-dependent toxicity model
4. Cerebellar-thalamic-cortical circuit dysfunction — not isolated cortical pathology; the cerebellum is a key node
5. Excitation/inhibition imbalance — perampanel's efficacy confirms glutamatergic excess as an effector

7.2 Refuted Hypotheses

1. Gene loss-of-function — host gene expression is NOT altered in FAME
2. RAN translation — no repeat polypeptides detected (unlike C9orf72-ALS/FTD)
3. Haploinsufficiency — RAI1 levels normal in FAME8 (despite RAI1 haploinsufficiency causing Smith-Magenis syndrome)

7.3 Outstanding Questions

1. Why does the same TTTCA repeat cause FAME but not SCA37 (where ATTTC in DAB1 causes cerebellar ataxia via enhancer hyperactivation)?
2. What factors determine which of the seven genes acquires the TTTCA insertion in different populations?
3. Is there a minimum pathogenic TTTCA repeat length? (Affected individuals with as few as 9 TTTCA repeats have been reported)
4. Can UUUCA RNA foci or aberrant splicing patterns serve as biomarkers?
5. Why is FAME generally benign/non-progressive while other RNA foci diseases (e.g., DM1) are progressive?

8. Figures

The following figures were generated during this investigation:

1. FAME Genetic Subtypes and Pathomechanism Pathway — Overview of all 7 subtypes and step-by-step RNA toxicity mechanism
2. Genotype-Phenotype Correlation and Clinical Features — TTTCA count vs. onset age; frequency of clinical features
3. Comprehensive Disease Overview Infographic — All key disease characteristics in one view
4. NOVA2 Protein Interaction Network — STRING database network showing epilepsy gene connections
5. Geographic Distribution and Disorder Comparison — Regional clustering of subtypes; FAME vs. related repeat diseases
6. Diagnostic and Therapeutic Landscape — Clinical pathway from suspicion to confirmation; treatment options

9. Limitations

1. No experimental data analyzed: This characterization is literature-based; no primary data files were available
2. NOVA2 network analysis is correlational: STRING interactions suggest but don't prove that NOVA2 disruption alters splicing of specific epilepsy genes in FAME
3. Limited epidemiological data: True prevalence unknown; no formal natural history studies exist
4. Publication bias: Most literature from East Asian and European centers; other populations underrepresented
5. Rapid-evolving field: New FAME loci and mechanistic insights continue to emerge

10. References (Key Papers)

1. Ishiura H, et al. (2018) Expansions of intronic TTTCA and TTTTA repeats in benign adult familial myoclonic epilepsy. Nat Genet. PMID: 29507423
2. Corbett MA, et al. (2023) Genetics of familial adult myoclonus epilepsy: From linkage studies to noncoding repeat expansions. Epilepsia. PMID: 37021642
3. Chen L, et al. (2025) (TTTCA)exp Drives the Genotype-Phenotype Correlation and Genetic Anticipation in FCMTE1. PMID: 39569876
4. Zhang Y, et al. (2026) RNA Toxicity and Interacting RNA-Binding Protein NOVA2 of (UUUCA)exp RNA Foci in Familial Cortical Myoclonic Tremor with Epilepsy. PMID: 41850906
5. Ding J, et al. (2024) Seizures and electrophysiological features in familial cortical myoclonic tremor with epilepsy 1. PMID: 38059543
6. Cuccurullo E, et al. (2023) Familial adult myoclonus epilepsy: A non-coding repeat expansion disorder of cerebellar-thalamic-cortical loop. PMID: 37371086
7. Yeetong P, et al. (2024) Pentanucleotide repeat insertions in RAI1 cause benign adult familial myoclonic epilepsy type 8. PMID: 37994247
8. Coppola A, et al. (2025) Clinical efficacy of low-dose Perampanel correlates with neurophysiological changes in FAME2. PMID: 39533755
9. Urabe T, et al. (2025) Targeted nanopore long-read sequencing panel for the molecular diagnosis of FAME. PMID: 41219789
10. Chen J, et al. (2025) Origin and evolution of pentanucleotide repeat expansions at the FCMTE1-SAMD12 locus. PMID: 38467733
11. Baykan B, et al. (2023) Differential diagnosis of familial adult myoclonic epilepsy. PMID: 36751956
12. Uzun A, et al. (2023) Familial adult myoclonic epilepsy: Clinical and genetic approach to an under-recognized disease. PMID: 37287551
13. Depienne C, et al. (2023) Insights into FAME pathogenesis: How the same repeat expansion in six unrelated genes may lead to cortical excitability. PMID: 36622139
14. Meldolesi J (2020) Alternative splicing by NOVA factors. PMID: 32486302
15. Saito Y, et al. (2019) Differential NOVA2-mediated splicing in excitatory and inhibitory neurons. PMID: 30638744
16. Loureiro JR, et al. (2026) ATTTC repeat insertion in Alu element hyperactivates a neurodevelopmental enhancer in SCA37. PMID: 41871099
17. Zeng Y, et al. (2025) Phenotypic and genotypic characterization of FAME in a Chinese case series. PMID: 40503331
18. Perera D, et al. (2025) First clinical diagnosis of FAME3 via commercial long-read sequencing. PMID: 40788430

Report generated by autonomous scientific discovery agent. Investigation conducted across 3 iterations with 12 confirmed findings based on review of ~30 published papers, database queries (NCBI, UniProt, STRING, ClinicalTrials.gov, Wikidata), and computational network analysis.